Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of burosumab in adults with X-linked hypophosphatemia
2014-005529-11Phase 3Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of burosumab in X-linked hypophosphataemia (XLH) (3 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Serum phosphorus response. Started Aug 2015; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)
Beyond the preview
Go deeper on 2014-005529-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005529-11.